Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine
About this episode
The episode discusses significant biotech news including a historic IPO, AI collaborations, and clinical trial results for a dual vaccine.
We are still talking about big pharma deals and biotech fundraising in this episode. The big news this week was Parabilis Medicines’s history-making IPO. We dive into the drug developer’s plans for the eye-popping $770.5 million that it raised. Next, we discuss the details of a collaboration between Merck and Protillion Biosciences to use artificial intelligence to discover multiple therapeutic candidates. Turning to some newly published research, we discuss the early results of a first-in-human clinical trial that is testing a dual vaccine against Lassa fever and rabies, a CRISPR system engineered to selectively trigger cancer cell death by chromatin shredding, and a novel mRNA delivery platform for delivering gene therapies starting with Duchenne muscular dystrophy. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Uduak Thomas, and Fay Lin, PhD, for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base : StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO By Alex Philippidis, GEN Edge , June 14, 2026 Merck, Protillion…
More episodes of Touching Base
- Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics
- Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Diseases
Explore listener stats, chart rankings, contacts and more on the Touching Base podcast page.